Genetikai marker-vizsgálatok fej-nyaki daganatokban

Translated title of the contribution: Genetic marker analysis in head and neck cancer

O. Csuka, Olasz Judit, Juhász Alíz, Hargitai Árpád, E. Remenár, M. Kásler

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Prognostication of head and neck cancer (HNCC) involves molecular identification of residual tumor cells, prediction of recurrence, distant metastases or secondary tumors and prediction of the sensitvity to therapy. Biomarkers of HNCC are mutations of p53, p16 and amplification of Cyclin D and E2F4. One hundred and fifty-two HNCC cases have been evaluated for p53, hMLH1, Cyclin D and p16 gene alterations using PCR-SSCP and Western blot analysis. P53 mutations of HNCC have been found in 37.5% of cases. However, 11% of the cases showed p53 mutations in the normal peritumoral mucosa suggesting "field cancerization" process. Mismatch-repair gene mutations (MMR: hMHL1 and hMSH2) occurred with 17 and 8.6% frequency, respectively, while E2F4 mutations were even more frequent (21.4%) in HNCC. Our data suggest that E2F4 overexpression can be caused by the inactivation of the p16 gene in HNCC, while its mutations are most probably associated to the mutations of the MMR genes. These molecular informations can help to predict the biological potential of HNCC as well as the probability of the development of secondary HNCCs.

Original languageHungarian
Pages (from-to)161-167
Number of pages7
JournalMagyar Onkologia
Volume45
Issue number2
Publication statusPublished - 2001

Fingerprint

Head and Neck Neoplasms
Genetic Markers
Mutation
Cyclin D
p16 Genes
Single-Stranded Conformational Polymorphism
DNA Mismatch Repair
Residual Neoplasm
Genes
Mucous Membrane
Biomarkers
Western Blotting
Neoplasm Metastasis
Recurrence
Polymerase Chain Reaction
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Genetikai marker-vizsgálatok fej-nyaki daganatokban. / Csuka, O.; Judit, Olasz; Alíz, Juhász; Árpád, Hargitai; Remenár, E.; Kásler, M.

In: Magyar Onkologia, Vol. 45, No. 2, 2001, p. 161-167.

Research output: Contribution to journalArticle

Csuka, O, Judit, O, Alíz, J, Árpád, H, Remenár, E & Kásler, M 2001, 'Genetikai marker-vizsgálatok fej-nyaki daganatokban', Magyar Onkologia, vol. 45, no. 2, pp. 161-167.
Csuka, O. ; Judit, Olasz ; Alíz, Juhász ; Árpád, Hargitai ; Remenár, E. ; Kásler, M. / Genetikai marker-vizsgálatok fej-nyaki daganatokban. In: Magyar Onkologia. 2001 ; Vol. 45, No. 2. pp. 161-167.
@article{c84c9311cb9b4346b382691ef204c9ef,
title = "Genetikai marker-vizsg{\'a}latok fej-nyaki daganatokban",
abstract = "Prognostication of head and neck cancer (HNCC) involves molecular identification of residual tumor cells, prediction of recurrence, distant metastases or secondary tumors and prediction of the sensitvity to therapy. Biomarkers of HNCC are mutations of p53, p16 and amplification of Cyclin D and E2F4. One hundred and fifty-two HNCC cases have been evaluated for p53, hMLH1, Cyclin D and p16 gene alterations using PCR-SSCP and Western blot analysis. P53 mutations of HNCC have been found in 37.5{\%} of cases. However, 11{\%} of the cases showed p53 mutations in the normal peritumoral mucosa suggesting {"}field cancerization{"} process. Mismatch-repair gene mutations (MMR: hMHL1 and hMSH2) occurred with 17 and 8.6{\%} frequency, respectively, while E2F4 mutations were even more frequent (21.4{\%}) in HNCC. Our data suggest that E2F4 overexpression can be caused by the inactivation of the p16 gene in HNCC, while its mutations are most probably associated to the mutations of the MMR genes. These molecular informations can help to predict the biological potential of HNCC as well as the probability of the development of secondary HNCCs.",
author = "O. Csuka and Olasz Judit and Juh{\'a}sz Al{\'i}z and Hargitai {\'A}rp{\'a}d and E. Remen{\'a}r and M. K{\'a}sler",
year = "2001",
language = "Hungarian",
volume = "45",
pages = "161--167",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Genetikai marker-vizsgálatok fej-nyaki daganatokban

AU - Csuka, O.

AU - Judit, Olasz

AU - Alíz, Juhász

AU - Árpád, Hargitai

AU - Remenár, E.

AU - Kásler, M.

PY - 2001

Y1 - 2001

N2 - Prognostication of head and neck cancer (HNCC) involves molecular identification of residual tumor cells, prediction of recurrence, distant metastases or secondary tumors and prediction of the sensitvity to therapy. Biomarkers of HNCC are mutations of p53, p16 and amplification of Cyclin D and E2F4. One hundred and fifty-two HNCC cases have been evaluated for p53, hMLH1, Cyclin D and p16 gene alterations using PCR-SSCP and Western blot analysis. P53 mutations of HNCC have been found in 37.5% of cases. However, 11% of the cases showed p53 mutations in the normal peritumoral mucosa suggesting "field cancerization" process. Mismatch-repair gene mutations (MMR: hMHL1 and hMSH2) occurred with 17 and 8.6% frequency, respectively, while E2F4 mutations were even more frequent (21.4%) in HNCC. Our data suggest that E2F4 overexpression can be caused by the inactivation of the p16 gene in HNCC, while its mutations are most probably associated to the mutations of the MMR genes. These molecular informations can help to predict the biological potential of HNCC as well as the probability of the development of secondary HNCCs.

AB - Prognostication of head and neck cancer (HNCC) involves molecular identification of residual tumor cells, prediction of recurrence, distant metastases or secondary tumors and prediction of the sensitvity to therapy. Biomarkers of HNCC are mutations of p53, p16 and amplification of Cyclin D and E2F4. One hundred and fifty-two HNCC cases have been evaluated for p53, hMLH1, Cyclin D and p16 gene alterations using PCR-SSCP and Western blot analysis. P53 mutations of HNCC have been found in 37.5% of cases. However, 11% of the cases showed p53 mutations in the normal peritumoral mucosa suggesting "field cancerization" process. Mismatch-repair gene mutations (MMR: hMHL1 and hMSH2) occurred with 17 and 8.6% frequency, respectively, while E2F4 mutations were even more frequent (21.4%) in HNCC. Our data suggest that E2F4 overexpression can be caused by the inactivation of the p16 gene in HNCC, while its mutations are most probably associated to the mutations of the MMR genes. These molecular informations can help to predict the biological potential of HNCC as well as the probability of the development of secondary HNCCs.

UR - http://www.scopus.com/inward/record.url?scp=34948844020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948844020&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 161

EP - 167

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -